Search clinical trials for: chemotherapy response

Total 25018 results

M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Molecular Testing and Imaging in Improving Response in Patients With Stage I-III Triple-Negative Breast Cancer Receiving Chemotherapy MDACC Breast Moonshot Initiative

Invasive Breast Carcinoma | Triple-Negative Breast Carcinoma | Stage I Breast Cancer AJCC v7 | Stage IA Breast Cancer AJCC v7 | Stage IB Breast Cancer AJCC v7 | Stage II Breast Cancer AJCC v6 and v7 | Stage IIA Breast Cancer AJCC v6 and v7 | Stage IIB Breast Cancer AJCC v6 and v7 | Stage III Breast... and other conditions

United States
Sun Yat-sen University
Zhejiang Cancer Hospital; First People's Hospital of Hangzhou; The First Affiliated... and other collaborators

Recruiting

Neoadjuvant Chemoradiotherapy vs. Chemotherapy With Radical Gastrectomy and Adjuvant Chemotherapy for Advanced Gastric Cancer (Neo-CRAG)

Gastric Cancer

China
Poitiers University Hospital

Recruiting

Study of Immune Response and Liver Damage Induced by Chemotherapy for Liver Metastases of Colorectal Cancer (METAHEP)

Resectable Hepatic Metastases of Colorectal Cancer

France
Ding Ma
Shandong University; Wuhan University; Sun Yat-sen University; Zhejiang University and other collaborators

Recruiting

Model Development and Prospective Validation to Predict the Response to Neoadjuvant Chemotherapy in Cervical Cancer

Cervical Cancer

China
National Cancer Institute (NCI)

Not yet recruiting

Biomarkers in Predicting Treatment Response in Samples From Patients With Early-Stage Non-Small Cell Lung Cancer Previously Treated With Adjuvant Chemotherapy

Stage IIIA Non-small Cell Lung Cancer | Stage IA Non-small Cell Lung Cancer | Stage IB Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung Cancer

Canada
QuantumLeap Healthcare Collaborative

Recruiting

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer (I-SPY)

Breast Cancer | Breast Neoplasms | Breast Tumors | HER2-positive Breast Cancer | Angiosarcoma | Locally Advanced Breast Cancer | HER2-negative Breast Cancer | TNBC - Triple-Negative Breast Cancer | Hormone Receptor Positive Tumor | Hormone Receptor Negative Tumor | Early-stage Breast Cancer

United States
SWOG Cancer Research Network
National Cancer Institute (NCI)

Completed

S1314, Co-expression Extrapolation (COXEN) Program to Predict Chemotherapy Response in Patients With Bladder Cancer (COXEN)

Bladder Cancer

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy

Edema | Erythema | Estrogen Receptor Negative | HER2/Neu Negative | Progesterone Receptor Negative | Triple-Negative Breast Carcinoma | Recurrent Inflammatory Breast Carcinoma | Stage IV Inflammatory Breast Carcinoma | Peau d'Orange

United States
Boston Medical Center
American Cancer Society, Inc.

Enrolling by invitation

Monitoring Neoadjuvant Chemotherapy Response in Breast Cancer Patients Using Diffuse Optical Spectroscopic Imaging (DOSI)

Breast Cancer

United States
Roswell Park Cancer Institute

Active, not recruiting

Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant

Hodgkin Lymphoma | Waldenstrom Macroglobulinemia | Non-Hodgkin Lymphoma | Myelodysplastic Syndrome | Plasma Cell Myeloma | Myeloproliferative Neoplasm | Minimal Residual Disease | Graft Versus Host Disease | Severe Aplastic Anemia | Acute Myeloid Leukemia in Remission | Adult Acute Lymphoblastic Leukemia... and other conditions

United States
AstraZeneca
Merck Sharp & Dohme LLC; GOG Foundation; Myriad Genetic Laboratories, Inc.

Active, not recruiting

Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy. (SOLO-1)

Advanced Ovarian Cancer | Newly Diagnosed | FIGO Stage III-IV | Partial Response | Complete Response | BRCA Mutation | First Line Platinum Chemotherapy

Korea, Republic of, France, Italy, United States, Israel, Canada, China, Brazil, United Kingdom, Poland, Australia, Japan, Netherlands, Russian Federation, Spain
M.D. Anderson Cancer Center

Active, not recruiting

Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia | Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Philadelphia Chromosome Positive | B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 | Untreated Adult Acute Lymphoblastic Leukemia | Accelerated Phase Chronic Myelogenous Leukemia,... and other conditions

United States
Indiana University
Purdue University

Terminated

Biodynamic Imaging Utility in Predicting Response to Gemcitabine Chemotherapy in Mycosis Fungoides (BDI)

Lymphoma, T-Cell, Cutaneous | Mycosis Fungoides

United States
AstraZeneca

Active, not recruiting

Olaparib Tablets Maintenance Monotherapy Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy (L-MOCA)

Relapsed Ovarian Cancer | Following Complete or Partial Response to Platinum Based Chemotherapy | Platinum Sensitive

China, Malaysia
University College, London
Cancer Research UK; Cancer Research UK & UCL Cancer Trials Centre

Completed

Fludeoxyglucose F 18-PET/CT Imaging in Assessing Response to Chemotherapy in Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Hodgkin Lymphoma

Lymphoma

United Kingdom
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

DCE-MRI and MBI in Assessing Tumor Response to Chemotherapy in Patients With Triple Negative Breast Cancer

Estrogen Receptor Negative | HER2/Neu Negative | Progesterone Receptor Negative | Triple-Negative Breast Carcinoma

United States
National Taiwan University Hospital
Ministry of Science and Technology, Taiwan

Completed

The Prediction Model of NAC Response for Breast Cancer Based on The Parametric Dynamics Features.

Breast Cancer | Chemotherapy Effect | PET Imaging | Multiparametric Magnetic Resonance Imaging | Diffusion Weighted MRI
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Atorvastatin in Treating Patients With Stage IIb-III Triple Negative Breast Cancer Who Did Not Achieve a Pathologic Complete Response After Receiving Neoadjuvant Chemotherapy

Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIC Breast Cancer AJCC v8 | Prognostic Stage IIB Breast Cancer AJCC v8 | Prognostic Stage III Breast Cancer... and other conditions

United States
American College of Radiology Imaging Network
National Cancer Institute (NCI)

Completed

DWI in Assessing Treatment Response in Patients With Breast Cancer Receiving Neoadjuvant Chemotherapy (ACRIN6698)

Breast Cancer

United States
Tesaro, Inc.
Gynecologic Oncology Group; European Network of Gynaecological Oncological... and other collaborators

Active, not recruiting

A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

Ovarian Neoplasms

United States, Spain, Finland, Czechia, Italy, Denmark, Germany, Belgium, Israel, Canada, Russian Federation, Sweden, United Kingdom, Poland, Ireland, Ukraine, France, Norway, Switzerland, Hungary
AstraZeneca
Merck Sharp & Dohme LLC; European Network of Gynaecological Oncological Trial... and other collaborators

Active, not recruiting

Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy

Relapsed Ovarian Cancer | Following Complete or Partial Response to Platinum Based Chemotherapy | Platinum Sensitive | BRCA Mutated

Korea, Republic of, France, China, Italy, United States, Israel, United Kingdom, Canada, Japan, Germany, Brazil, Netherlands, Belgium, Poland, Australia, Russian Federation, Spain
University of Southern California
National Cancer Institute (NCI); Mayo Clinic

Active, not recruiting

Controlled Low Calorie Diet in Reducing Side Effects and Increasing Response to Chemotherapy in Patients With Breast or Prostate Cancer

Breast Cancer | Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer

United States
National Cancer Institute (NCI)

Active, not recruiting

FLT PET/CT in Measuring Response in Patients With Previously Untreated Acute Myeloid Leukemia

Acute Myeloid Leukemia

United States
University Hospital, Bordeaux

Active, not recruiting

Optimisation of Response for Organ Preservation in Rectal Cancer : Neoadjuvant Chemotherapy and Radiochemotherapy vs. Radiochemotherapy (GRECCAR12)

Rectal Cancer

France
Genentech, Inc.

Completed

A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response (MyTACTIC)

Advanced Unresectable or Metastatic Solid Malignancy

United States
Pfizer
Astellas Pharma Inc

Active, not recruiting

Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC

Prostate Cancer

United States, Finland, China, France, Spain, Hungary, United Kingdom, Korea, Republic of, Canada, Czechia, Taiwan, Belgium, Australia, Argentina, Japan, Germany, India, Turkey, Slovakia, Russian Federation, Bulgaria, Italy, Ukraine, ... and more
Florence Nightingale Hospital, Istanbul

Completed

Vitamin D Can Increase Pathological Response of the Breast Cancer Patients Treated With Neoadjuvant Therapy

Vitamin D Deficiency | Chemotherapy Effect | Pathology

Turkey
Masonic Cancer Center, University of Minnesota

Active, not recruiting

Assessment of Complete Pathologic Response After Neoadjuvant Chemotherapy for Breast Cancer

Triple Negative Breast Cancer | HER2-positive Breast Cancer | TN ER-/PR-/HER2- Breast Cancer | ERany/PRany/HER2+ Breast Cancer

United States
MedSIR

Active, not recruiting

Chemotherapy-free Trastuzumab and Pertuzumab in HER2-positive Breast Cancer: FDG-PET Response-adapted Strategy. (PHERGain)

Breast Cancer

Spain, Italy, France, United Kingdom, Germany, Portugal, Belgium
Centre Georges Francois Leclerc

Active, not recruiting

Study Evaluating the Utility of 18F-FDG PET in Assessing Early Response to Neoadjuvant Chemotherapy in Patients With Mammary Gland Cancer (TREN)

FDG PET

France
Cordgenics, LLC

Completed

Standard Chemotherapy vs. Chemotherapy Guided by Cancer Stem Cell Test in Recurrent Glioblastoma (CSCRGBM)

Recurrent Glioblastoma

United States
Addario Lung Cancer Medical Institute
Biodesix, Inc.

Terminated

Biomarker Analysis in High PD-L1 Expressing NSCLC Patients Treated With PD-1/PD-L1 Based Therapy With or Without the Addition of Platinum Based Chemotherapy (BEACON-LUNG)

NSCLC Stage IV | NSCLC, Stage IIIC

United States
Lund University Hospital

Active, not recruiting

Irinotecan-based Triplet (FOLFOXIRI) as Perioperative Treatment in Resectable Gastric and Gastroesophageal Junction Adenocarcinoma. (INTENSE)

Resectable Gastric and Gastroesophageal Junction Adenocarcinoma

Sweden, Norway
Institut Curie

Completed

Assessment of Response to Neo-adjuvant Chemotherapy for Patients With a Locally Advanced Breast Cancer With 3D Elastography (Shear Wave), (NEO-ELASTO)

Breast Neoplasms

France
Jeong Eon Lee
Asan Medical Center; Seoul National University Hospital; Gangnam Severance Hospital and other collaborators

Active, not recruiting

Selective Avoidance of Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy In HER-2 Positive/Triple Negative Breast Cancer Patients With Excellent Radiologic Response to the Breast and Axilla, Prospective, Multi-center, Single-arm (ASLAN) Study (ASLAN)

Breast Cancer

Korea, Republic of
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Pembrolizumab in Treating Patients With Hormone Receptor Positive, Localized Inflammatory Breast Cancer Who Are Receiving Hormone Therapy and Did Not Achieve a Pathological Complete Response to Chemotherapy

Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIC Breast Cancer AJCC v8 | Prognostic Stage IIIB Breast Cancer AJCC v8 | Prognostic Stage IIIC Breast Cancer AJCC v8 | Breast Inflammatory Carcinoma

United States
DKMS gemeinnützige GmbH

Completed

Impact of Remission Induction Chemotherapy Prior to Allogeneic SCT in Relapsed and Poor-response Patients With AML (ETAL3-ASAP)

Acute Myeloid Leukemia

Germany
Fundación GECP

Active, not recruiting

New Adjuvant Trial of Chemotherapy vs Chemo-immunotherapy (NADIM-ADJUVANT)

Non-Small Cell Lung Cancer | Adjuvant Chemotherapy

Spain
Cliniques universitaires Saint-Luc- Université...

Terminated

Predictive Value of ProCalcitonin for the Detection of Bacteraemia in Patients Presenting to the Emergency Department for Low Risk Chemo-induced Febrile Neutropenia (CALIF)

Febrile Neutropenia, Drug-Induced

Belgium
Acıbadem Atunizade Hospital

Completed

Muscle Parameters and Pathological Response in Breast Cancer Patients

Neoadjuvant Chemotherapy

Turkey
Johns Hopkins University

Completed

Sodium Citrate 4% Locking Solution for Children Requiring Home Parenteral Nutrition

CLABSI - Central Line Associated Bloodstream Infection

United States
PhytoHealth Corporation

Terminated

Complementary Treatment of PG2 to Improve Clinical Benefit Response and Quality of Life in Fatigue

Quality of Life | Fatigue | Complementary

Taiwan
PhytoHealth Corporation

Completed

PG2 Phase I/II Clinical Study Intravenously Administered in Patients With Advanced Malignancy

Neoplasm Metastasis | Neoplasm Recurrence

Taiwan
University Health Network, Toronto
Pancreatic Cancer Canada

Active, not recruiting

GATA6 Expression as a Predictor of Response to Peri-Operative Chemotherapy in Resectable Pancreatic Adenocarcinoma (NeoPancOne)

Resectable Pancreatic Cancer

Canada
Shanghai Jiao Tong University School of Medicine

Completed

Neoadjuvant Toripalimab and Paclitaxel/Cisplatin on Pathological Response in Oral Squamous Cell Carcinoma Patients

Oral Cancer | Induction Chemotherapy | Programmed Cell Death 1 Inhibitor | Inductive Therapy

China
Leiden University Medical Center
The Netherlands Cancer Institute; Borstkanker Onderzoek Groep; Comprehensive... and other collaborators

Suspended

Fasting Mimicking Diet Program to ImpRovE ChemoTherapy in Hormone Receptor Postive (HR+), HER2- Breast Cancer (DIRECT-2)

HER2-negative Breast Cancer | Hormone Receptor-positive Breast Cancer | Neoadjuvant Chemotherapy | Fasting Mimicking Diet | Pathological Complete Response | Objective Response Rate

Netherlands
University of Arizona

Terminated

Correlate BRCA1 Protein Expression With Response to DNA Damaging Chemotherapy

Breast Cancer

United States
Children's Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome

Acute Myeloid Leukemia | Down Syndrome | Myelodysplastic Syndrome | Myeloproliferative Neoplasm | Myeloid Leukemia Associated With Down Syndrome

United States, Canada, Saudi Arabia, Puerto Rico, Australia, New Zealand
Memorial Sloan Kettering Cancer Center

Active, not recruiting

Evaluate The Accuracy Of Breast MRI Biopsy In Diagnosing A Complete Tumor Response For Some Women Following Neoadjuvant Chemotherapy For Breast Cancer

Breast Cancer

United States
Sun Yat-sen University
First Affiliated Hospital, Sun Yat-Sen University; Sun Yat-Sen Memorial Hospital...

Active, not recruiting

ACHP-THP vs EC-THP as Neoadjuvant Therapy for HER2-positive EBC

Breast Cancer | Neoadjuvant Chemotherapy

China

Search clinical trials for: chemotherapy response

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Guinea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations